Compare Organon & Co. Common Stock (OGN) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Tapestry, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Tapestry, Inc. trades at $115.86 (market cap $22.87B). The key difference: Tapestry, Inc. is far larger — about 6.3× Organon & Co. Common Stock's market cap, and Tapestry, Inc. pays the higher dividend (1.61%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Tapestry, Inc. for 70 Days on average.
| OGN | TPR | |
|---|---|---|
Market Cap | $3.62B | $22.87B |
Volume | 2,892,999 | 1,963,570 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $164.78 |
52-Week Low | $5.70 | $98.81 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $11.04B | $25.67B |
Dividend Yield | 0.58% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TPR trades at $115.23, down 1.7% today, with neutral technical signals and strong analyst support. The stock shows robust profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include expansion into Google's AI shopping ecosystem and accelerating international growth in China and Europe. The company maintains a solid balance sheet with $1.12 billion in cash and manageable debt levels.
TPR presents a compelling investment case with 73% analyst buy ratings and a $174.64 consensus price target representing 52% upside. Strong brand momentum and margin expansion potential are offset by tariff risks and Kate Spade execution challenges. The stock trades at reasonable valuations with a 15.85 P/E ratio, though recent net income decline from $816M to $183M warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
